This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Burny, W. Articles by Saint-Remy, J-M. Search for Related Content PubMed PubMed Citation Articles by Burny, W. Articles by Saint-Remy, J-M. Social Bookmarking                         What's this?

Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice

Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven

P. Lebrun

Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven

J-P. Cosyns

Pathology Unit, Cliniques Saint-Luc, Université catholique de Louvain, Brussels, Belgium

J-MR Saint-Remy

Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven

Lupus nephritis results from the deposition on the glomerular basement membrane of antibodies cross-reacting with dsDNA. In an attempt to suppress the production of such antibodies in the MRLlpr mouse strain, mice were treated by injections of dsDNA-anti-dsDNA antibody complexes formed in an excess of syngeneic polyclonal antibodies to increase the immunogenicity of idiotypes.

A first group of mice was treated after the onset of high-affinity anti-dsDNA IgG antibodies (3 months). We show here that fortnightly injections of dsDNA-anti-dsDNA antibody complexes significantly extend mouse survival over that of two control groups treated with either the carrier buffer or with sham complexes. Treated mice produced 5-fold less anti-dsDNA antibodies than control mice and presented a reduced nephritis activity index at the age of 7 months. Specific anti-idiotypic antibody levels were not modified in the treated group, while showing a sharp decrease in the control group between months 6 and 7.

Mice of a second group were started on injections of dsDNA-anti-dsDNA complexes at the age of 4 months when nephritis was already ongoing, and were followed until death while receiving fortnightly injections. Forty percent of the treated mice were still alive after one year, while none of the control mice survived.

dsDNA-anti-dsDNA complexes have therefore the potential of reducing the production of anti-dsDNA antibody production and the severity of nephritis in MRLlpr mice. These findings could be relevant for the treatment of human lupus.

Key Words: systemic lupus erythematosus • MRLlpr mouse strain • Ag-Ab complexes.

Lupus, Vol. 6, No. 1, 4-17 (1997)
DOI: 10.1177/096120339700600102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Mihaylova, E. Voynova, A. Tchorbanov, M. Nikolova, A. Michova, T. Todorov, L. Srebreva, H. Taskov, and T. Vassilev Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc{gamma}IIb receptor Int. Immunol., February 1, 2008; 20(2): 165 - 175. [Abstract] [Full Text] [PDF]

				M. Hundt, K. Manger, T. Dorner, B. Grimbacher, P. Kalden, A. Rascu, D. Weber, G. R. Burmester, H. H. Peter, J. R. Kalden, et al. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin Rheumatology, November 1, 2000; 39(11): 1301 - 1302. [Full Text] [PDF]

				M. L. Stoll and J. Gavalchin Systemic lupus erythematosus--messages from experimental models Rheumatology, January 1, 2000; 39(1): 18 - 27. [Full Text] [PDF]